Interview with Mats Persson, new Member of the Board in Follicum

June 12, 2019

Interview with Mats Persson, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum?
I have more than 35 years of experience in marketing and licensing within the global pharmaceutical industry. Today, I hold the position as Head of Nordic at Tesaro, an American biotech company in oncology, recently acquired by GSK. I have extensive experience from senior positions at Astellas Pharma Norden/Baltic (CEO), Novo Nordisk, Pharmacia Corporation and Ferring International. I am also a Board Member of Gedea Biotech AB as well as Nordic Rebalance a/s and I own MS Persson Consulting AB where I support Companies within Strategy, Marketing and Sales.

Why did you join Follicum as a Board Member?
It is an interesting company, with 2 very exciting drug candidates, both in areas where there is a high unmet medical need. There are very few alternatives to treat hair loss today and it seems as Follicum has one of the few clinical candidates with a clear promise of delivering a safe, effective and convenient hair growth product. The recent patent application for the topical formulation strengthens the case further. Follicum is starting a POC trial this year that will read out already 2020 and this will be extremely interesting to follow! I am very excited that Follicum is pursuing diabetic complications with their novel peptides and that they already have identified a drug candidate. This is something that Big Pharma is looking for!

What expertise will you bring to the Follicum Board?
My experience is mainly on the commercial side. I have broad experience in how to launch products successfully and how to build competitive organisations. I am interested in the life science area in general, especially indications where there is a high unmet medical need, or less effective/safe treatment alternatives today where Follicum’s two indication areas hair growth and diabetic complications fits very nicely. I have a diploma in Management and Corporate Governance from EFL, Lund 2017, and have board experience from small start-up companies within Life Science, so I hope to bring that experience to the table in Follicum.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 (0)46 – 19 21 97
Email: info@follicum.com

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com

Open Interview